A Closer Look: Roche’s Move On Danoprevir Shines Light On Innovation Strategy In China
This article was originally published in PharmAsia News
Executive Summary
Roche Pharmaceuticals Asia Pacific Head Luke Miels talks to PharmAsia News about the company’s recent deal with Ascletis, its thinking on China’s hepatitis C market and additional opportunities for out-licensing.